Wuxi International Life Sciences Innovation Park

The Wuxi International Life Science Innovation Campus (I·Campus, ) originated from the founding of the Wuxi Science and Technology Entrepreneurship Park in 1993, the city's inaugural national-level incubator. In 2010, it was classified as a provincial-level life sciences industrial park by the Jiangsu Provincial Department of Science and Technology. In 2015, it was elevated to the status of the National Torch Program's Specialized Industry Base for Biomedicine and Medical Devices in Wuxi New District. In March 2019, at the Boao Forum for Asia, a strategic partnership agreement was executed between Wuxi High-tech Zone and AstraZeneca to collaboratively build the park into a comprehensive platform encompassing research and development, incubation, and commercialization.

History

The park was officially inaugurated in September 2019. In 2020, it was integrated into the provincial demonstration zone for biomedical innovation, collaboratively formed by the Jiangsu Medical Products Administration and Wuxi City, thereby expediting its internationalization.

The campus adheres to a "1+2+X" master plan configuration, consisting of one industrial cluster zone, two innovation bases, and several core ecosystem circles. It seeks to achieve 5 million square meters of area and an industrial output of RMB 135 billion by 2025. It has established about 640,000 square meters of operational space, comprising a 300,000-square-meter research and development and business area, a 92,000-square-meter pilot testing and acceleration zone, and a newly constructed 200,000-square-meter phase II facility that commenced operations in 2024. The second phase, intended for integrated application in research and development, production, and office operations—boasting increased floor height, load-bearing capacity, dual freight elevators, and two-level basements—secured over 90% pre-leasing prior to its inauguration. The campus has attracted more than 500 enterprises and institutions by concentrating on four primary sectors: biopharmaceuticals, medical equipment, specialized medical foods, and smart healthcare. Prominent entities encompass AstraZeneca, Hangzhou Tigermed, the Yangtze Delta Institute of Peking University for Life and Health Technologies, and the China Pharmaceutical University Research Institute.